Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT03944265
Official study title

Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer

Study summary

This trial studies the use of genetics and shared decision making in improving care for patients with stage IVA-C non-small cell lung cancer. Developing educational tools may help patients with non-small cell lung cancer to increase patient treatment knowledge, reduce decisional conflict, and promote treatment shared decision making with their health care providers.

Ask AI to explain this study
Start here

Key things to know

Main goalSupportive Care

This describes the study’s primary purpose.

What is being studiedCounseling and Questionnaire Administration

Plus 1 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Apr 29, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Thomas Jefferson University

Study sponsor

01
Study overview

What this study is about

Purpose
Supportive Care
Study type
Interventional
Phase
Not applicable
Sponsor
Thomas Jefferson University
Interventions being studied
Other: Counseling; Other: Questionnaire Administration; Other: Medical Chart Review
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Metastatic or stage IV→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Newly diagnosed with advanced NSCLC (stage IV a-c) that are wild-type for activating genetic alterations (EGFR, ROS 1, and ALK).
  • May or may not be candidates for immune checkpoint therapy.
  • May have had 1-any number of prior systemic therapy regimens.
  • If prior systemic regimen, must have progression disease at time of evaluation.
  • Untreated brain metastases permitted.
  • Completed pathological analysis of tumor tissue.
  • Patients who have exhausted targeting therapy options.
  • Can speak and read English.
  • All participants must be willing to comply with all study procedures and be available for the duration of the study.
  • Providers: Those who treat NSCLC patients as described above.
Reasons someone may not be able to joinExclusion criteria

There are no specific exclusions in this trial for particular medical conditions, comorbidities, or performance status. Any patient deemed appropriate to be considered for evaluation and/or treatment would be appropriate to include in this trial.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Sidney Kimmel Cancer Center at Thomas Jefferson UniversityPhiladelphia, Pennsylvania

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 29, 2025. Always confirm current availability with the study team.

View original record ↗